MEMarta Elosua‐González

Marta Elosua‐González

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Marta Elosua‐González has a total of 120 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Longitudinal Effectiveness and Laboratory Safety Profile of Janus Kinase Inhibitors in Moderate-to-Severe Atopic Dermatitis: A Real-World Study

    by Carolina Montero-Vílchez, Alberto Ruiz-Jiménez, Marta Elosua-Gonzalez, Salvador Arias-Santiago, Trinidad Montero-Vílchez

    Background/Objectives: Janus kinase inhibitors (JAKis) are effective treatments for moderate-to-severe atopic dermatitis (AD), although longitudinal real-world data on their laboratory safety profile remain limited and there is scarce information regarding whether laboratory changes differ according to JAKi use. So, the main objective of this study was to evaluate longitudinal laboratory changes in patients with AD treated with JAKis in routine clinical practice and to evaluate these changes across different types of JAKis. Methods: We conducted a retrospective observational study including patients with moderate-to-severe AD who initiated treatment with abrocitinib, upadacitinib, or baricitinib. Demographic, clinical, laboratory, and patient-reported outcome data were collected at baseline and after 4, 12–16, 24–32, and 48–52 weeks. Longitudinal changes were analyzed using REML mixed-effects models with categorical visit and a patient-specific random intercept, using logarithmic transformations for skewed laboratory parameters. Results: Forty-three patients were included. EASI decreased from 21.18 ± 8.82 at baseline to 6.06 ± 8.27 at week 4 and 7.85 ± 8.63 at weeks 48–52, while pruritus NRS decreased from 7.15 ± 2.48 to 2.23 ± 2.78 and 4.34 ± 3.28, respectively (p < 0.001). At weeks 24–32, total cholesterol (+29.26), LDL cholesterol (+16.09), HDL cholesterol (+6.57), and MCV (+2.12) increased significantly, whereas CRP (−2.87), leukocyte (−1.07), and neutrophil counts (−1.07) decreased significantly. Mean creatinine changes were small. No significant longitudinal changes were observed in AST, ALT, triglycerides or hemoglobin. Few between-treatment differences were identified. No MACE, VTE or changes in lipid-lowering treatment were documented during recorded follow-up. Conclusions: JAKis provided substantial clinical benefit with a favorable longitudinal laboratory safety profile. Laboratory abnormalities were generally mild and consistent with the known safety profile of this class.

  • Open Access

    Dupilumab in Difficult-to-treat Chronic Spontaneous Urticaria: A Real-world Multicentre Cohort Study

    by Nidia Planella-Fontanillas, Emilio Berna-Rico, Ignasi Figueras-Nart, Jorge Spertino, Lluís Dols Casanova, María Elena Gatica Ortega, Vicente Expósito-Serrano, Miguel Antonio Lasheras Pérez, Mercedes Rodríguez Serna, José M. Mascaró Jr., et al.

    Chronic spontaneous urticaria (CSU) remains difficult to manage in patients refractory to antihistamines and omalizumab. Although dupilumab has recently been approved and incorporated into international guidelines, real-world evidence remains limited, particularly in treatment-refractory populations. We conducted a multicentre ambispective cohort study across 16 Spanish hospitals including adults with CSU, with or without concomitant chronic inducible urticaria, treated with dupilumab and followed for ≥4 weeks. The primary outcome was well-controlled disease within 24 weeks (Urticaria Control Test ≥12 and Urticaria Activity Score over 7 days≤6). Fiftyone patients were included; 92.0% had previously received omalizumab. At week 24, 69.7% (23/33) achieved well-controlled disease and 39.4% (13/33) complete control. Among patients with available week-52 data, 90.5% (19/21) and 61.9% (13/21), respectively, achieved these outcomes. Concomitant therapy use declined from 94.1% at baseline to 55.6% at week 52. Among omalizumab-experienced patients evaluable at week 24, dupilumab response was lower in prior nonresponders than in those with at least partial response to omalizumab (40% vs 85%, p=0.011). Atopic comorbidities were associated with greater UAS7 reduction (p=0.018). Dupilumab was well tolerated, with mostly mild adverse events. In routine clinical practice, dupilumab provides effective disease control in patients with difficult-totreat CSU, including most omalizumab-experienced individuals.

  • Combination of advanced systemic therapy in atopic dermatitis: A multicentre observational study

    by Marta Elosua‐González, Trinidad Montero‐Vilchez, Constanza Riquelme‐Mc Loughlin, Ana Royuela, Fátima Tous‐Romero, Ignasi Figueras‐Nart, Alberto Guerrero‐Torija, Vanesa Fatsini‐Blanch, Berta Pérez‐Tato, María Dorado, et al.

  • Allergic Contact Dermatitis to Bakuchiol Used for Photodamage Prevention: A Case Report

    by Manuel Sánchez‐Arjona, Ángel Manuel Rosell‐Díaz, Juan Luis Castaño‐Fernández, Marta Elosua‐González

  • Open Access

    Clinical Factors Associated With Current Relevance in Allergic Contact Dermatitis: Development of Predictive Models Based on Data From the Spanish Contact Dermatitis Register ( REIDAC )

    by David Pesqué, Francisco Javier Ortiz de Frutos, Francisco Navarro‐Triviño, Tatiana Sanz‐Sánchez, Violeta Zaragoza‐Ninet, Susana Córdoba‐Guijarro, Javier Miquel‐Miquel, Juan Francisco Silvestre‐Salvador, Ricardo González‐Pérez, Inmaculada Ruiz‐González, et al.

    Background: Current relevance of positive patch‐test reactions guides management in allergic contact dermatitis (ACD), yet its clinical predictors and the use of predictive models in clinical practice remain underused. Objectives: To identify demographic and clinical factors associated with current relevance in ACD and to develop overall and allergen‐specific predictive models. Methods: A multicentric REIDAC study included data from patch‐tested patients with the Spanish baseline series. Exposure history, anatomical sites, atopic status, and occupational data were recorded. Logistic regression (LR) models were trained and internally validated to predict current relevance overall and for top frequent allergens. Model discrimination was assessed with area under the receiver‐operating characteristic curve (AUC). Results: Among 17 005 patients, 4077 (24.0%) had at least one currently relevant reaction. The final overall LR model achieved an AUC for the validation sample of 0.679. Allergen‐specific AUC parameters (LR) varied among allergens but performed best for nickel (AUC = 0.770). The independent factors associated with current relevance were female gender, specific body sites (hand, neck, head, leg, feet) and two occupations (hairdresser and construction workers). The use of other models (LASSO, gradient boosting) revealed similar results. Conclusions: Prediction modelling may moderately predict current relevance in ACD and several clinical variables are associated with current relevance in ACD.


  • An emerging epidemic of allergic contact dermatitis due to phytonadione epoxide (oxidised vitamin K1)

    by María E. Gatica‐Ortega, María A. Pastor‐Nieto, Ana María Giménez‐Arnau, Pedro Mercader‐García, Esther Serra‐Baldrich, Violeta Zaragoza‐Ninet, Tatiana Sanz‐Sánchez, Araceli Sánchez‐Gilo, David Pesqué, Fátima Tous‐Romero, et al.

    Background: Reports of allergic contact dermatitis (ACD) to phytonadione epoxide (PE) in cosmetics suggest that PE is as powerful a sensitiser as its parent compound phytonadione.Objective: To evaluate a case series of ACD to PE in Spain.Methods: We reviewed the records of 20 patients with ACD to cosmetics containing PE diagnosed across Spain between January 2019 and June 2023.Results: All 20 patients developed patch test (PT) or repeated open application test (ROAT) reactions to cosmetics containing PE. All involved women with eyelid eczema. PT or ROAT with PE preparations were positive in 17/20 (85%). PE at 1%, 5%, 10% and 20% in pet. was patch‐tested in 8/17, 14/17, 11/17 and 8/17 patients; being positive in 6/8 (75%), 13/14 (92.85%), 11/11 (100%) and 8/8 (100%), respectively.Conclusion: Regulators should, not only ban the specific dangerous cosmetic ingredients, but also consider to ban or keep under close surveillance those closely related products or derivatives that might potentially cause similar harmful effects. PTs with PE are suggested to be performed at a 5% concentration in pet. Higher concentrations (10% pet.) should be tested whenever PTs with 5% pet. PE are negative.


  • Sonography of monkeypox cutaneous lesions

    by F. J. Rodríguez-Cuadrado, J. L. Castaño-Fernández, M. Elosua-González, G. Roustan-Gullón, F. Alfageme-Roldán

    The present global outbreak of monkeypox has reached more than 79,000 cases by November 2022. While clinical features have been extensively studied, ultrasound findings in monkeypox skin lesions have not been described to date. In our work, we performed a complete sonographic study with Doppler and elastography of 3 patients with polymerase chain reaction-proven monkeypox. The most characteristic findings in skin lesions were hyperechoic epidermal thickening, dermo-hypodermal thickening with focal hypoechogenicity and increased intralesional vascularization. Regarding lymphadenopathies, we found vascularization of hilar distribution and an increased cortical stiffness and shoft hiliar area.


  • Dermatoscopic features in monkeypox

    by Francisco J. Rodríguez‐Cuadrado, Marta Elosua‐González, Gaston Roustan‐Gullón, Fernando Alfageme‐Roldán


  • Open Access

    Remissão clínica de infecção disseminada por molusco contagioso em paciente com dermatite atópica tratada com dupilumabe

    by Marta Elosua‐González, Ángel Rosell‐Díaz, Fernando Alfageme‐Roldán, Mercedes Sigüenza‐Sanz, Gaston Roustan‐Gullón

  • Open Access

    Clinical remission of disseminated molluscum contagiosum infection in a patient with atopic dermatitis treated with dupilumab

    by Marta Elosua-González, Ángel Rosell-Díaz, Fernando Alfageme-Roldán, Mercedes Sigüenza-Sanz, Gaston Roustan-Gullón